ArticleInternational journal of clinical and experimental pathology2019
miR-539-3P inhibits proliferation and invasion of gastric cancer cells by targeting CTBP1.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 8 citations in OpenAlex.
- NAD(H)-dependent corepressor CTBP1 integrates metabolic signals to drive oncogenic programs.Frontiers in immunology · 2026Review
- MiR-539-3p Alleviates Apoptosis and Extracellular Matrix Degradation in Chondrocytes of Childhood-Onset Osteoarthritis by Targeting RUNX2.Physiological research · 2024Article
- MiR-539-3p inhibited chondrogenic differentiation in human adipose stem cells by targeting Sox9.Journal of orthopaedic surgery and research · 2022Article
- MiR-539-3p impairs osteogenesis by suppressing Wnt interaction with LRP-6 co-receptor and subsequent inhibition of Akap-3 signaling pathway.Frontiers in endocrinology · 2022Article
- Circ_0004104 Accelerates the Progression of Gastric Cancer by Regulating the miR-539-3p/RNF2 Axis.Digestive diseases and sciences · 2021Article
- CTBP1 strengthens the cisplatin resistance of gastric cancer cells by upregulating RAD51 expression.Oncology letters · 2021Article
- Predicting Associations of miRNAs and Candidate Gastric Cancer Genes for Nanomedicine.Nanomaterials (Basel, Switzerland) · 2021Article
- The anti-tumor effect of miR-539-3p on colon cancer via regulating cell viability, motility, and nude mouse tumorigenicity with CDK14 inhibition.Journal of gastrointestinal oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is the fifth most lethal carcinoma in the world. Genetic and epigenetic factors transform the normal cells into malignant cells and lead to tumor development. MicroRNA (miRNA), a small non-coding RNA which functions in RNA silencing and post-transcriptional regulation of gene expression, is closely associated with cancer initiation and propagation, including stomach cancer. In this study, for the first time, we report miR-539-3P, as a tumor suppressor, was down-regulated in gastric cancer both
Indexed as
Identifiers
31933979PMC6947129W3005712129What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.